Design (Testphase)
Breakout & Setup
Tight Weekly Range (WCR≥90)
221
Hits
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 25 hits from US
Weekly Closing Range ≥ 90 and Daily Closing Range ≥ 70 — a very tight, strong weekly range closing near the high.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(15)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines Inc | 08/03 | +177 % | 96 10/22 | Stage 2 | C +7 | 4 of 9 | 9.1 | Biotechnology | – | — | — | Healthcare | 304.40 $ | +3.6 % | +27.6 % | +642.1 % | −10.6 % | +88.8 % | 98 | 42 | 6.8 % | 7.0 % | 2.76 | — | 0.0 | — | 6.1 | — | — | -6.9 | 0.0 % | -3,809.4 % | 0.0 % | -35.3 % | -23.0 % | 0.00 | 96.6 % | -100.0 % | 0.0 % | 0.0 % | 31.8 | 116.8 % | 12.8 % | 1.2 (12) |
| SLS Sellas Life Sciences Group Inc | 08/11 | +148 % | — | Stage 2 | C +5 | 3 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 12.50 $ | +140.6 % | +444.0 % | +436.3 % | −4.8 % | -5.0 % | 98 | 50 | 12.4 % | 11.1 % | 2.43 | — | 0.0 | — | — | — | — | -1.7 | 0.0 % | — | 0.0 % | -43.6 % | -25.5 % | — | 94.1 % | -100.0 % | 0.0 % | 0.0 % | 16.0 | 27.6 % | 32.4 % | 1.0 (3) |
| WYY Widepoint C | 08/13 | +242 % | 92 10/25 | Stage 2 | C +3 | 5 of 9 | 0.2 | Information Technology Services | – | — | — | Technology | 11.60 $ | +184.4 % | +194.6 % | +459.4 % | −16.9 % | -3.5 % | 98 | 13 | 16.8 % | 12.9 % | 1.71 | — | 18.2 | 1.3 | — | 25.7 | 2.33 | 117.4 | — | 13.9 % | -1.2 % | -15.8 % | -1.6 % | — | — | +5.6 % | 0.0 % | 0.0 % | -0.1 | 18.7 % | 3.5 % | — |
| RVMD Revolution Medicines Inc | 08/05 | +188 % | 38 4/22 | Stage 2 | D -18 | 1 of 9 | 37.1 | Biotechnology | – | — | — | Healthcare | 180.40 $ | +112.8 % | +137.2 % | +324.0 % | −3.4 % | +10.7 % | 97 | 42 | 4.8 % | 4.4 % | 1.38 | — | 0.0 | — | 25.8 | — | — | -9.7 | 0.0 % | -151,691.8 % | 0.0 % | -76.7 % | -37.5 % | 0.29 | 66.6 % | -100.0 % | 0.0 % | 0.0 % | 1.4 | 95.7 % | 6.1 % | 1.0 (12) |
| RLAY Relay Therapeutics Inc | 08/06 | +16 % | 88 8/22 | Stage 2 | D -48 | 3 of 9 | 3.9 | Biotechnology | – | — | — | Healthcare | 19.20 $ | +106.1 % | +128.2 % | +457.9 % | −5.9 % | +39.2 % | 97 | 42 | 6.4 % | 8.1 % | 1.68 | — | 0.0 | 360.2 | — | — | — | -0.8 | -2,619.7 % | -2,300.3 % | 0.0 % | -40.0 % | -24.7 % | — | 91.8 % | +53.4 % | 0.0 % | 0.0 % | 8.5 | 87.0 % | 20.4 % | 1.2 (13) |
| MBX MBX Biosciences, Inc. Common Stock | 08/06 | — | 69 6/22 | Stage 2 | D -33 | 3 of 9 | 2.3 | Biotechnology | – | — | — | Healthcare | 60.10 $ | +47.1 % | +67.7 % | +397.4 % | −4.1 % | +37.2 % | 97 | 42 | 8.5 % | 7.7 % | — | — | 0.0 | — | 5.5 | — | — | 0.0 | 0.0 % | — | 0.0 % | -25.7 % | -17.7 % | 0.00 | 96.7 % | — | 0.0 % | 0.0 % | 37.2 | 111.5 % | 16.8 % | 1.0 (5) |
| BIOA BioAge Labs, Inc | 08/05 | — | — | Stage 2 | C -3 | 4 of 9 | 0.0 | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 22.30 $ | +68.7 % | +77.2 % | +426.0 % | −9.3 % | +118.8 % | 97 | 50 | 8.5 % | 7.7 % | — | — | 0.0 | — | 2.8 | — | — | 0.0 | — | -707.2 % | 0.0 % | -26.0 % | -17.2 % | 0.01 | — | -100.0 % | 0.0 % | 0.0 % | 26.5 | 85.5 % | 5.1 % | — |
| GLUE Monte Rosa Therapeutics Inc | 08/06 | +19 % | — | Stage 2 | D -30 | 4 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 23.50 $ | +32.1 % | +35.5 % | +349.4 % | −16.0 % | +53.1 % | 96 | 50 | 8.1 % | 6.8 % | 1.56 | — | 10.9 | — | 3.4 | — | — | 51.9 | — | -238.5 % | 0.0 % | -32.6 % | -16.4 % | 0.08 | — | +63.5 % | 0.0 % | 0.0 % | 7.7 | 113.2 % | 20.7 % | — |
| BLZE Backblaze Inc | 08/06 | +57 % | 62 6/25 | Stage 3 | B +16 | 5 of 9 | 0.8 | Software - Infrastructure | Uses AI | — | Technology | 13.20 $ | +150.2 % | +211.9 % | +134.3 % | −8.2 % | +2.1 % | 96 | 42 | 14.6 % | 9.7 % | 1.55 | — | 178.6 | 5.1 | — | 55.9 | — | 149.5 | — | 62.3 % | -15.0 % | -27.6 % | -5.2 % | — | — | +14.3 % | 0.0 % | 0.0 % | -0.3 | 48.9 % | 2.6 % | — | |
| ELVN Enliven Therapeutics Inc. | 08/12 | +44 % | 69 6/22 | Stage 2 | D -44 | 4 of 9 | 3.3 | Biotechnology | – | — | — | Healthcare | 51.70 $ | +215.6 % | +203.9 % | +135.4 % | −2.8 % | +32.6 % | 95 | 42 | 6.6 % | 6.9 % | 0.26 | — | 0.0 | — | 7.9 | — | — | -6.3 | 0.0 % | — | 0.0 % | -26.6 % | -18.9 % | 0.00 | 97.5 % | — | 0.0 % | 0.0 % | 47.0 | 89.7 % | 11.1 % | 1.0 (8) |
| NVCT Nuvectis Pharma Inc | 08/04 | +1 % | 82 7/22 | Stage 2 | E -54 | 1 of 9 | 0.9 | Biotechnology | – | — | — | Healthcare | 18.00 $ | +132.5 % | +270.0 % | +207.5 % | −0.2 % | +4.8 % | 95 | 42 | 16.4 % | 9.8 % | -0.25 | — | 0.0 | — | — | — | — | -7.4 | — | — | 0.0 % | -154.4 % | -63.6 % | — | — | -100.0 % | 0.0 % | 0.0 % | -7.1 | 18.2 % | 10.1 % | — |
| OSCR Oscar Health Inc | 08/05 | +84 % | 79 7/22 | Stage 2 | B +28 | 7 of 9 | 8.2 | Healthcare Plans | Uses AI | — | — | Healthcare | 29.60 $ | +108.3 % | +97.3 % | +42.8 % | −5.6 % | -21.2 % | 94 | 87 | 5.6 % | 6.6 % | 2.34 | — | 588.2 | 0.6 | 5.3 | 2.9 | — | 0.0 | 15.2 % | 17.4 % | -0.3 % | -2.6 % | 0.1 % | 0.26 | 17.9 % | +27.5 % | 0.0 % | 0.0 % | 3.0 | 67.6 % | 7.1 % | 1.9 (7) |
| URGN UroGen Pharma Ltd | 08/06 | +18 % | 69 6/22 | Stage 2 | B +13 | 3 of 9 | 1.7 | Biotechnology | Uses AI | — | — | Healthcare | 41.10 $ | +50.1 % | +51.8 % | +147.7 % | −4.7 % | +8.0 % | 94 | 42 | 5.1 % | 5.4 % | 1.58 | — | 0.0 | 11.8 | — | — | — | -2.6 | -39.8 % | 89.9 % | -94.8 % | -1,481.3 % | -27.0 % | — | -49.0 % | +21.5 % | 0.0 % | 0.0 % | -8.0 | 100.6 % | 13.7 % | 1.3 (8) |
| TMCI Treace Medical Concepts Inc | 08/06 | -28 % | 40 4/22 | Stage 3 | D -35 | 4 of 9 | 0.3 | Medical Devices | Neutral | — | Healthcare | 4.20 $ | +83.3 % | +75.0 % | -28.1 % | −42.8 % | -10.1 % | 94 | 42 | 10.5 % | 9.8 % | 1.38 | — | 0.0 | 1.2 | 3.5 | — | — | -40.9 | — | 79.7 % | -29.4 % | -66.9 % | -17.9 % | 0.18 | — | +1.6 % | 0.0 % | 0.0 % | 0.4 | 57.1 % | 6.3 % | — | |
| RCUS Arcus Biosciences Inc | 08/05 | +16 % | 40 4/22 | Stage 2 | D -34 | 0 of 9 | 3.8 | Biotechnology | Neutral | — | Healthcare | 28.20 $ | +18.3 % | +34.4 % | +233.7 % | −3.8 % | +18.2 % | 93 | 42 | 6.2 % | 6.0 % | 0.80 | — | 0.0 | 16.1 | 7.4 | — | — | 4.0 | -788.2 % | -121.6 % | -156.4 % | -70.0 % | -23.1 % | 0.22 | 52.6 % | -4.3 % | 0.0 % | 0.0 % | 1.0 | 72.4 % | 17.4 % | 1.2 (13) | |
| CGEM Cullinan Oncology LLC | 08/06 | +14 % | 55 5/22 | Stage 2 | C -6 | 1 of 9 | 1.1 | Biotechnology | – | — | — | Healthcare | 17.50 $ | +71.5 % | +79.5 % | +132.9 % | −1.5 % | +70.7 % | 93 | 42 | 8.3 % | 8.2 % | -0.01 | — | 6.7 | — | — | — | — | -1.5 | — | — | 0.0 % | -48.2 % | -30.6 % | — | — | -100.0 % | 0.0 % | 0.0 % | 10.2 | 107.8 % | 18.9 % | — |
| JBIO Jade Biosciences, Inc. | 08/12 | -21 % | 55 5/22 | Stage 2 | E -53 | 2 of 9 | 1.2 | Biotechnology | – | — | — | Healthcare | 19.70 $ | +42.4 % | +33.8 % | +121.9 % | −22.1 % | +122.4 % | 93 | 42 | 9.6 % | 9.1 % | — | — | 0.0 | — | 4.5 | — | — | 0.0 | — | — | 0.0 % | -89.2 % | -33.6 % | 0.00 | — | — | 0.0 % | 0.0 % | 18.0 | 84.8 % | 10.1 % | — |
| INSW International Seaways Inc | 08/05 | +79 % | 79 3/10 | Stage 2 | B +26 | 7 of 9 | 4.0 | Oil & Gas Midstream | – | — | — | Energy | 88.40 $ | +102.2 % | +76.8 % | +153.1 % | −12.1 % | +13.9 % | 92 | 95 | 5.0 % | 4.2 % | -0.10 | — | 6.0 | 4.0 | — | 32.7 | — | 5.8 | 61.3 % | 67.7 % | 55.3 % | 26.9 % | 10.5 % | — | 76.4 % | -11.4 % | 4.7 % | 97.8 % | 11.0 | 80.8 % | 6.2 % | 1.0 (6) |
| MRX Marex Group plc Ordinary Shares | 08/12 | — | 79 7/22 | Stage 2 | B +21 | 4 of 9 | 4.5 | Capital Markets | – | — | — | Financial Services | 62.60 $ | +74.6 % | +49.3 % | +72.9 % | −4.8 % | -7.8 % | 92 | 79 | 4.9 % | 4.7 % | -0.09 | 14.5 | 8.8 | 0.8 | 3.4 | — | — | 6.1 | 13.1 % | 68.9 % | 10.6 % | 29.1 % | 1.1 % | — | 3.7 % | +25.4 % | 1.0 % | 13.3 % | 4.2 | 75.2 % | 4.6 % | 1.1 (8) |
| NAT Nordic American Tankers Limited | — | +50 % | 98 5/10 | Stage 2 | C +9 | 7 of 9 | 1.3 | Oil & Gas Midstream | – | — | — | Energy | 6.20 $ | +102.0 % | +83.4 % | +168.5 % | −6.6 % | -4.2 % | 92 | 97 | 5.9 % | 4.4 % | -0.55 | — | 10.0 | 3.8 | — | — | 1.21 | 17.3 | 49.5 % | 46.9 % | 16.4 % | 11.4 % | 4.7 % | — | 50.6 % | -16.4 % | 15.2 % | 3.4 % | 6.0 | 50.0 % | 10.9 % | 1.7 (3) |
| KGS Kodiak Gas Services, Inc. | 08/05 | — | 98 5/10 | Stage 2 | B +11 | 7 of 9 | 7.4 | Oil & Gas Equipment & Servic | – | — | — | Energy | 64.50 $ | +94.9 % | +106.1 % | +116.8 % | −4.8 % | +13.7 % | 91 | 17 | 4.1 % | 3.8 % | 0.82 | 93.0 | 32.1 | 5.6 | 6.4 | 36.8 | — | 17.7 | 33.7 % | 64.2 % | 5.1 % | 5.4 % | 6.0 % | 0.06 | 26.1 % | +12.8 % | 2.8 % | 120.8 % | 4.2 | 91.3 % | 8.5 % | 1.2 (11) |
| OMER Omeros Corporation | 08/13 | -8 % | 80 7/22 | Stage 1 | B +32 | 6 of 9 | 0.8 | Biotechnology | – | — | — | Healthcare | 9.60 $ | -39.0 % | -35.5 % | +231.7 % | −39.3 % | +207.8 % | 91 | 42 | 10.1 % | 8.1 % | 2.55 | 7.6 | 58.1 | 78.5 | 8.4 | — | 0.81 | -1.5 | — | -190.5 % | 871.0 % | -576.3 % | -25.2 % | -4.91 | — | -100.0 % | 0.0 % | 0.0 % | -1.8 | 44.5 % | 25.9 % | — |
| ALKS Alkermes Plc | 08/04 | +15 % | 68 6/22 | Stage 2 | C 0 | 1 of 9 | 8.8 | Drug Manufacturers - Special | – | — | — | Healthcare | 51.70 $ | +71.8 % | +84.2 % | +72.4 % | −1.6 % | -5.0 % | 90 | 9 | 4.8 % | 4.2 % | 0.29 | 61.2 | 142.9 | 5.6 | 5.3 | 39.7 | 1.96 | 36.8 | -0.2 % | 87.5 % | 9.8 % | 9.4 % | 4.7 % | 0.90 | 41.1 % | -5.3 % | 0.0 % | 0.0 % | 4.9 | 110.5 % | 15.0 % | 1.4 (15) |
| INDV Indivior PLC Ordinary Shares | 07/30 | +25 % | 68 6/22 | Stage 2 | B +22 | 4 of 9 | 4.7 | Drug Manufacturers - Special | Neutral | — | Healthcare | 39.10 $ | +11.4 % | +14.1 % | +197.3 % | −1.9 % | +23.1 % | 90 | 83 | 3.6 % | 3.6 % | 1.15 | 21.5 | 13.0 | 3.6 | 145.3 | — | — | 14.2 | 46.1 % | 85.0 % | 19.5 % | 12.2 % | 22.7 % | -3.49 | -12.0 % | +4.3 % | 0.0 % | 0.0 % | 3.6 | 107.5 % | 11.9 % | 1.0 (7) | |
| CLPT Clearpoint Neuro Inc | 08/11 | +61 % | 40 4/22 | Stage 3 | D -13 | 4 of 9 | 0.5 | Medical Devices | Neutral | — | — | Healthcare | 15.10 $ | +35.5 % | +34.1 % | +58.3 % | −40.3 % | +57.8 % | 90 | 42 | 11.6 % | 9.0 % | 1.24 | — | 12.1 | 13.4 | 28.7 | — | 0.61 | -7.1 | — | 62.3 % | -71.6 % | -149.7 % | -25.0 % | 3.38 | — | +17.8 % | 0.0 % | 0.0 % | -3.1 | 50.6 % | 17.0 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Weekly Closing Range ≥ 90 and Daily Closing Range ≥ 70 — a very tight, strong weekly range closing near the high.
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 221 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
Related scanners
- ATH
- Ants
- Ben Bennett: Power of Four
- Bullish Reversal Bar
- Gap-Up (≥3%)
- Green Line Breakout
- High ADR — Hot Theme
- Inside Day
- Inside Day at Highs
- Mark Minervini: Power Play
- Oliver Kell: Bull Snorts
- Oliver Kell: Gappers
- Oops Reversal
- Pocket Pivot
- Pradeep Bonde: $ Breakout Bullish
- Pradeep Bonde: 4% Breakout Bullish
- Qullamaggie: Continuation Base
- Qullamaggie: Episodic Pivot
- Qullamaggie: High Tight Flag
- Strong DCR (≥80)
- Tight & Near High
- Tight Weekly Closes
- Volume Surge
- Volume Surge
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.